365 related articles for article (PubMed ID: 33188037)
1. Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells.
Sun R; Sundahl N; Hecht M; Putz F; Lancia A; Rouyar A; Milic M; Carré A; Battistella E; Alvarez Andres E; Niyoteka S; Romano E; Louvel G; Durand-Labrunie J; Bockel S; Bahleda R; Robert C; Boutros C; Vakalopoulou M; Paragios N; Frey B; Soria JC; Massard C; Ferté C; Fietkau R; Ost P; Gaipl U; Deutsch E
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188037
[TBL] [Abstract][Full Text] [Related]
2. Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy.
Sun R; Lerousseau M; Briend-Diop J; Routier E; Roy S; Henry T; Ka K; Jiang R; Temar N; Carré A; Laville A; Hamaoui A; Laurent PA; Rouyar A; Robert C; Robert C; Deutsch E
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36307149
[TBL] [Abstract][Full Text] [Related]
3. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer: A machine learning, multicenter study.
Yu Y; He Z; Ouyang J; Tan Y; Chen Y; Gu Y; Mao L; Ren W; Wang J; Lin L; Wu Z; Liu J; Ou Q; Hu Q; Li A; Chen K; Li C; Lu N; Li X; Su F; Liu Q; Xie C; Yao H
EBioMedicine; 2021 Jul; 69():103460. PubMed ID: 34233259
[TBL] [Abstract][Full Text] [Related]
5. CT-based radiomics signature to predict CD8+ tumor infiltrating lymphocytes in non-small-cell lung cancer.
Chen Y; Xu T; Jiang C; You S; Cheng Z; Gong J
Acta Radiol; 2023 Apr; 64(4):1390-1399. PubMed ID: 36120843
[TBL] [Abstract][Full Text] [Related]
6. Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.
Han X; Guo Y; Ye H; Chen Z; Hu Q; Wei X; Liu Z; Liang C
Breast Cancer Res; 2024 Jan; 26(1):18. PubMed ID: 38287356
[TBL] [Abstract][Full Text] [Related]
7. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.
Ligero M; Garcia-Ruiz A; Viaplana C; Villacampa G; Raciti MV; Landa J; Matos I; Martin-Liberal J; Ochoa-de-Olza M; Hierro C; Mateo J; Gonzalez M; Morales-Barrera R; Suarez C; Rodon J; Elez E; Braña I; Muñoz-Couselo E; Oaknin A; Fasani R; Nuciforo P; Gil D; Rubio-Perez C; Seoane J; Felip E; Escobar M; Tabernero J; Carles J; Dienstmann R; Garralda E; Perez-Lopez R
Radiology; 2021 Apr; 299(1):109-119. PubMed ID: 33497314
[TBL] [Abstract][Full Text] [Related]
8. Radiomics signature for dynamic changes of tumor-infiltrating CD8+ T cells and macrophages in cervical cancer during chemoradiotherapy.
Huang K; Huang X; Zeng C; Wang S; Zhan Y; Cai Q; Peng G; Yang Z; Zhou L; Chen J; Chen C
Cancer Imaging; 2024 Apr; 24(1):54. PubMed ID: 38654284
[TBL] [Abstract][Full Text] [Related]
9. Toward prediction of abscopal effect in radioimmunotherapy: Pre-clinical investigation.
Mihaylov IB; Totiger TM; Giret TM; Wang D; Spieler B; Welford S
PLoS One; 2021; 16(8):e0255923. PubMed ID: 34428218
[TBL] [Abstract][Full Text] [Related]
10. Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.
Ou D; Blanchard P; Rosellini S; Levy A; Nguyen F; Leijenaar RTH; Garberis I; Gorphe P; Bidault F; Ferté C; Robert C; Casiraghi O; Scoazec JY; Lambin P; Temam S; Deutsch E; Tao Y
Oral Oncol; 2017 Aug; 71():150-155. PubMed ID: 28688683
[TBL] [Abstract][Full Text] [Related]
11. Immuno-genomic-radiomics to predict response of biliary tract cancer to camrelizumab plus GEMOX in a single-arm phase II trial.
Liu QP; Tang J; Chen YZ; Guo F; Ma L; Pan LL; Tian YT; Wu XF; Zhang YD; Chen XF
JHEP Rep; 2023 Jul; 5(7):100763. PubMed ID: 37333974
[TBL] [Abstract][Full Text] [Related]
12. MRI-derived radiomics assessing tumor-infiltrating macrophages enable prediction of immune-phenotype, immunotherapy response and survival in glioma.
Chen D; Zhang R; Huang X; Ji C; Xia W; Qi Y; Yang X; Lin L; Wang J; Cheng H; Tang W; Yu J; Hoon DSB; Zhang J; Gao X; Yao Y
Biomark Res; 2024 Jan; 12(1):14. PubMed ID: 38291499
[TBL] [Abstract][Full Text] [Related]
13. Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer.
Ji D; Song C; Li Y; Xia J; Wu Y; Jia J; Cui X; Yu S; Gu J
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33106387
[TBL] [Abstract][Full Text] [Related]
14. Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma.
Park KJ; Lee JL; Yoon SK; Heo C; Park BW; Kim JK
Eur Radiol; 2020 Oct; 30(10):5392-5403. PubMed ID: 32394281
[TBL] [Abstract][Full Text] [Related]
15. Radiomic signature based on CT imaging to distinguish invasive adenocarcinoma from minimally invasive adenocarcinoma in pure ground-glass nodules with pleural contact.
Jiang Y; Che S; Ma S; Liu X; Guo Y; Liu A; Li G; Li Z
Cancer Imaging; 2021 Jan; 21(1):1. PubMed ID: 33407884
[TBL] [Abstract][Full Text] [Related]
16. A radiomic signature model to predict the chemoradiation-induced alteration in tumor-infiltrating CD8
Jeon SH; Lim YJ; Koh J; Chang WI; Kim S; Kim K; Chie EK
Radiother Oncol; 2021 Sep; 162():124-131. PubMed ID: 34265357
[TBL] [Abstract][Full Text] [Related]
17. Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature.
Watanabe T; Firat E; Scholber J; Gaedicke S; Heinrich C; Luo R; Ehrat N; Multhoff G; Schmitt-Graeff A; Grosu AL; Abdollahi A; Hassel JC; von Bubnoff D; Meiss F; Niedermann G
Cancer Immunol Immunother; 2020 Sep; 69(9):1823-1832. PubMed ID: 32350591
[TBL] [Abstract][Full Text] [Related]
18. A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab.
Korpics MC; Polley MY; Bhave SR; Redler G; Pitroda SP; Luke JJ; Chmura SJ
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):189-195. PubMed ID: 32569799
[TBL] [Abstract][Full Text] [Related]
19. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
20. Preliminary Computed Tomography Radiomics Model for Predicting Pretreatment CD8+ T-Cell Infiltration Status for Primary Head and Neck Squamous Cell Carcinoma.
Wang CY; Ginat DT
J Comput Assist Tomogr; 2021 Jul-Aug 01; 45(4):629-636. PubMed ID: 34519454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
